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Abstract: The cholinergic hypothesis has been reported first being the cause of memory dysfunction in
the Alzheimer’s disease. Researchers around the globe have focused their attention on understanding
the mechanisms of how this complicated system contributes to processes such as learning, memory,
disorientation, linguistic problems, and behavioral issues in the indicated chronic neurodegenerative
disease. The present review reports recent updates in hybrid molecule design as a strategy for
selectively addressing multiple target proteins involved in Alzheimer’s disease (AD) and the study
of their therapeutic relevance. The rationale and the design of the bifunctional compounds will be
discussed in order to understand their potential as tools to investigate the role of the cholinergic
system in AD.
Keywords: AChE inhibitor; Alzheimer’s disease; bitopic ligand; cholinergic system; hybrid
molecules; muscarinic receptors; nicotinic receptors
1. Introduction
Alzheimer’s disease (AD) is the most common form of dementia among geriatric people since
the beginning of the 21st century. In 2016, over 47.5 million people around the world suffered from
dementia. The World Health Organization hypothesizes that the number may rise to 75.6 million
by 2030. The clinical condition of AD is characterized by a progressive loss of memory and other
intellectual abilities up to serious levels where the daily life is severely affected [1]. Of note, no
definitive cause and no known cure have been found yet.
The characteristic features of the neurodegenerative decline include a decrease in levels of
acetylcholine (ACh) followed by dysfunction and eventual death of cholinergic neurons. Furthermore,
soluble β-amyloid oligomers (sAβ), β-amyloid fibrils (fAβ) misfolding and aggregation as well
as formation of tau protein tangles in the nervous tissue of brain occur as a result of tau-protein
hyperphosphorylation [1–3]. Water-soluble Aβ aggregates, detected in human brain lysates
from AD patients, were found to be more toxic than their insoluble fibrillar counterparts by
Li et al. [4]. Several other co-factors were hypothesized, such as oxidative stress and heavy metal
dyshomeostasis [5].
Etiologic evidence exists between AD, cholinergic, and glutamatergic neurochemical systems.
ACh is a crucial neurotransmitter responsible for mental and learning abilities. In AD patients,
a dramatic decrease in cholinergic innervation in the cortex and the hippocampus is related to
the loss of neurons in the basal forebrain [6]. Presynaptic cholinergic dysfunctions, loss of the
cholinergic neural network, and overactivation of acetylcholinesterase (AChE), which leads to
weakened neurotransmission, support the cholinergic hypothesis of the disease. This assumption
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suggests that cholinergic restoration therapy could be useful for alleviating the cognitive symptoms [7].
Another neurochemical hypothesis is mediated by N-methyl-D-aspartate (NMDA). Glutamate is an
excitatory neurotransmitter for NMDA receptors which are essential in cognitive processes. However,
in addition to the physiological stimulation, glutamate receptors cause neuronal damage due to
excitotoxicity under certain circumstances [8].
The conventional pharmacotherapy of AD makes use of compounds which inhibit the enzyme
AChE (donepezil, rivastigmine, and galantamine) in order to increase the levels of acetylcholine in the
nervous tissue of the brain ((1–3), Figure 1). However, these compounds can improve the cognitive
deficits of the disease only for a couple of months before losing activity. The shortness of the effect could
be due to a decrease of the AChE itself in the relevant regions of the brain [9]. Later in time, another
drug was introduced for the treatment of AD, i.e., memantine ((4), Figure 1) being a glutamatergic
antagonist which protects nerve tissue against glutamate-mediated excitotoxicity. Unfortunately, both
classes of drugs only provide a symptomatic relief without preventing the progression of the disease,
a fact which is not surprising given the intricacy of the pathology. Thus, there is a desperate need to
find selective and powerful drugs to improve the treatment of AD [1].
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2. The Cholinergic Hypothesis of Memory Dysfunction
The substantial loss of presynaptic cholinergic neurons in human postmortem Alzheimer’s-diseased
brains, the dysfunction of cholinergic markers such as ACh, choline, and choline acetyl transferase (ChAT,
an enzyme responsible for ACh production) as well as the consequent loss of cognitive skills and the
mental improvement observed in patients upon artificial restoration of cholinergic activity unequivocally
confirm the validity of the cholinergic hypothesis in AD [2]. Acetylcholine receptors (AChRs) propagate
the cognitive ability and consist of two primary members namely muscarinic (mAChRs) and nicotinic
receptors (nAChRs). While mAChRs are G-protein coupled receptors (GPCRs), nAChRs are ligand
gated ion channels. After release, ACh is hydrolyzed to choline and acetate in the synaptic cleft by two
cholinesterases, i.e., the AChE and the butyrylcholinesterase (BChE) (see Figure 2). Over the course of
the disease, the concentration of AChE decreases by 85%, whereas high levels of BChE were found to
influence the aggregation of Aβ, the main component of the amyloid plaques found in the brains of
Alzheimer patients [11,12]. Furthermore, synaptic dysfunction and neuronal cell death in vitro [13–16] as
well as impaired behavioral performance in animal models [17–19] seem to be directly correlated with
sAβ aggregates [20]. For this reason, mAChRs, nAChRs, as well as the hydrolases AChE and BChE are
important targets in the treatment of AD [21–23].
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3. Hybrid Compounds as Drug Discovery Tools i
Due to the absolute rel f the cholinergic ystem in AD it may be desirable to address
the involved cholinergic receptors and enzyme simultaneously by means of a multi-target strategy
and/or selectively through a dualsteric approach. This can be realized by addressing different binding
pockets of the same protein’s surface with one hybrid molecule or different proteins involved in the
same pathology. “Bivalent ligand” and “hybrid” are the general terms defining compounds which are
composed of two functional pharmacophores linked by a spacer [25].
3.1. One Single Molecule—Different Targets
Because of the multifactorial dimension of AD and the difficulty to apply the classical “one
target—one disease” concept [26], the multitarget compounds approach has often been considered
in recent years [27]. In this review, only hybrids intended to activate the cholinergic system will
be described. The advantages of the multipotent strategy are obvious, but it remains absolutely
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challenging. In fact, molecular hybridization involves integration of the structure-activity relationships
of two individual chemical species into a single molecular entity which should result in a balance of
potency, efficacy, and selectivity for all the targets. The new hybrids can be designed with different
degrees of pharmacophore overlapping, with linking or merging techniques, and using distinct
connection positions of the active moieties. Furthermore, the combination of several pharmacophoric
units usually results in large molecules which have limits in terms of molecular weight, lipophilicity,
permeability of membranes, and hydrogen bonds acceptance and donation [27]. The technique lends
itself well to address the cholinergic system in AD by concomitant inhibition of AChE and direct
muscarinic and nicotinic activation.
3.2. One Single Molecule—Different Binding Pockets of a Protein’s Surface
As already mentioned, the hybridization strategy can be used to obtain molecules containing two
pharmacophoric entities able to bind topographically different binding sites of the same target protein,
e.g., the endogenous orthosteric site and the allosteric one. Allosterism, first defined to describe the
modification of any enzyme activity by the binding of ligands to sites that were different from the
substrate-binding site itself [28], is widely explored for GPCRs, representing the largest class of drug
targets in the human genome [25]. It provides the great opportunity of selectively affecting one GPCR
subtype and simultaneously avoiding the problem of targeting the structurally conserved orthosteric
binding site [29]. Novel drugs targeting GPCRs do not enter the market as frequent as expected due to
unwanted off-target effects resulting from the lack of selectivity within a distinct receptor family [30].
3.2.1. Allosteric Modulation
GPCRs constitute a superfamily of integral membrane proteins characterized by seven
transmembrane domains being connected by three extracellular (EL) and intracellular (IL) loops [31].
Allosteric modulators do not bind to the orthosteric binding site but act at a distinct binding site
(i.e., an allosteric site) to either potentiate or inhibit activation of the receptor by its endogenous
ligand [32]. An innovative perspective in drug development takes advantage of allosteric binding sites
which usually altered between the different receptor subtype throughout the evolutionary processes.
Conformational changes of the receptor upon allosteric ligand binding can modify the activity of
an orthosteric agent in terms of the binding affinity and/or the downstream efficacy. This means
emphasizing signals to some pathways over others among the various possible combinations which
are associated with receptor activation, a phenomenon known as bias signaling (cf. Figure 3) [33,34].
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Besides subtype selectivity, allosteric modulators offer the advantage of saturable effects.
Since most of them lack agonistic activity, they can perfectly “fine-tune” any orthosteric ligand activity
to a ceiling level above which no further modulation occurs; this means they can be administered with
higher doses and lower propensity to toxicity compared to classic agonists or antagonists [25].
Since the discovery of allosterism, several theories were postulated in order to identify and
quantify this phenomenon: Ehlert’s ternary complex model is one of the most significant methods
describing how two distinct ligands, orthosteric and allosteric, may influence the binding and
functioning of each other [36]. The cooperativity level, indicated by the cooperativity factor α,
distinguishes between positive and negative allosteric modulators (PAMs and NAMs) and neutral
allosteric ligands (NALs). It is important to keep in mind that the obtained cooperativity is
always referred to a single allosteric modulator for a specific orthosteric probe and that an accurate
interpretation of a combination of functional and binding assays is necessary to understand the actual
kind of modulation. Probe dependency and cooperativity reveal a new level of subtype selectivity
rather than affinity, a phenomenon which was termed “absolute subtype selectivity”. For example,
the binding of ACh is selectively enhanced at the M4 muscarinic receptor by thiochrome binding to
the allosteric site, even though this allosteric modulator shows almost equal affinity for all muscarinic
subtypes [37].
A particular beneficial therapeutic meaning may be associated with allosteric agonist compounds
which differ from pure allosteric modulators. They are able to directly activate a receptor by binding
to an allosteric binding site even in the absence of an orthosteric ligand. These allosteric agonists
might be more suitable for the treatment of AD, either because of the reduced endogenous tone of
neurotransmitters or even their complete lack [38].
3.2.2. Bitopic Ligand Principle
The structural diversity among the extracellular vestibules allowed an innovative medicinal
chemistry strategy for the design of novel ligands, i.e., hybrid compounds. They are characterized by
chemical fragments which allow an interaction with both orthosteric and allosteric recognition sites.
Merging the best of both allosteric and orthosteric worlds in one ligand launches the bitopic or
dualsteric compounds [39,40], a strategy derived from the “message-address” concept by Schwyzer [41]
which was first applied to GPCRs by Portoghese et al. [42]. This concept explicitly underlines the
orthosteric/allosteric combination, in opposite to the more general umbrella term bivalent [25].
The orthosteric interaction provides high affinity binding and activation/inhibition of a receptor
(message), whereas the allosteric interaction yields receptor subtype-selectivity (address) and may
modulate both efficacy and intracellular signaling pathway activation [43].
In fact, the transduction pathway of GPCRs include a large set of intracellular signaling proteins
like different G proteins, GRKs (protein coupled receptor kinase), and arrestins [44]. Such hybrid
molecules would allow to selectively identify therapeutically relevant signaling pathways, attenuate
harmful signals, or selectively block the ability of the agonist to produce unselective signals resulting
in side effects [45]. The recent functional screening of biased ligands using multiple assay formats
suggest that the phenomenon represents an existing and relevant therapeutic opportunity for the
treatment of different disorders [43]. The dualsteric principle was validated through numerous bitopic
ligands examples:
Iper-6-phth ((5a-C6), Figure 4) and iper-6-naph ((5b-C6), Figure 4) are derived from the M2
allosteric hexamethonium compounds W84 and naphmethonium (NAM regarding orthosteric agonists)
linked with the non-selective orthosteric superagonist iperoxo. The dualsteric compounds possess
relatively good selectivity for the M2 receptor regarding potency and affinity. Agonistic activation and
unexpected selectivity in the intracellular G protein pathway were observed: activation of Gi signaling
at the expense of the Gs.
Molecules 2018, 23, 3230 6 of 28
Molecules 2018, 23, x FOR PEER REVIEW  6 of 29 
 
a group 
X=H
b group
X=CH3
Ar =
N N
O
O
Br
Ar
X
X
N
O
O
N
Hybrid 1 5a-C6
Hybrid 2 5b-C6
Ar =
-
Br -
n
n = 6-10
 
Figure 4. Structures of bitopic hybrids. 5a-C6, 5b-C6 M2 muscarinic hybrid. Green: orthosteric 
building block, red: allosteric building block. 
Starting from the structure of the M2 preferring antagonist DIBA ((6), Figure 5), the homo-
dimeric dibenzodiazepinone derivatives UNSW-MK250 ((7), Figure 5) and UNSW-MK262 ((8), 
Figure 5) as well as the heterodimeric UR-SK75 ((9), Figure 5) compounds were prepared. All 
molecules exhibited high M2 receptor affinities and were capable of retarding [3H]NMS dissociation, 
indicating an allosteric interaction [46]. Saturation binding experiments in the presence of M2 
allosteric modulators and some radiolabeled dibenzodiazepinone compounds highlighted a 
competitive mechanism suggesting a dualsteric binding mode [47,48].  
N
HN
O
O
N
DIBA (6)
UNSW-MK250 (7)
N
NR
R R=
NR
N
N
O
NH
HN
O
O
NH
HN
O
N
N
UNSW-MK262 (8)
R
R
N
NR
O
N
SN
NUR-SK75 (9)  
Figure 5. Structures of homo-hetero dimeric dibenzodiazepinone M2 derivatives. 
Extending the approach to other GPCRs includes the adenosine A1 receptor with the dualsteric 
ligands LUF6258, VCP746 and VCP171 ((10, 11), Figure 6; VCP171, structure not disclosed). An 
orthosteric adenosine agonist was connected through an alkyl chain linker to a PAM of the PD81,723 
type. The resulting bitopic ligands were evaluated pharmacologically in radioligand displacement 
studies suggesting a dualsteric receptor interaction of LUF6258 [49]. VCP746 was subsequently 
Figure 4. Structures of bitopic hybrids. 5a-C6, 5b-C6 M2 muscarinic hybrid. Green: orthosteric
building block, red: allosteric building block.
Starting from the structure of the M2 prefe ring IB ( 6), Figure 5), the hom -dimeric
dibenzodiazepinone derivatives UNSW-MK250 ((7), Figure 5) and UNSW-MK262 ((8), Figure 5) as well
as the heterodimeric UR-SK75 ((9), Figure 5) compounds w re prepared. All mol cules exhibited high
M2 receptor affin ties and were c pable of retarding [3H]NMS dissociation, indicating an allosteric
in eraction [46]. Satura ion b nding experiments in the presence of M2 allosteric modulators and some
radiolabeled dibenzo iazepinone c mpounds highlighted a competitive mechanism suggesting a
dualst ric binding mode [47,48].
Molecules 2018, 23, x FOR PEER REVIEW  6 of 29 
 
a group 
X=H
b group
X=CH3
Ar =
N N
O
O
Br
Ar
X
X
N
O
O
N
Hybrid 1 5a-C6
Hybrid 2 5b-C6
Ar =
-
Br -
n
n = 6-10
 
Figure 4. Structures of bitopic hybrids. 5a-C6, 5b-C6 M2 muscarinic hybrid. Green: orthosteric 
building block, red: allosteric building block. 
Starting from the structure of the M2 preferring antagonist DIBA ((6), Figure 5), the homo-
dimeric dibenzodiazepinone derivatives UNSW-MK250 ((7), Figure 5) and UNSW-MK262 ((8), 
Figure 5) as well as the heterodimeric UR-SK75 ((9), Figure 5) compounds were prepared. All 
molecules exhibited high M2 receptor affinities and were capable of retarding [3H]NMS dissociation, 
indicating an allosteric interaction [46]. Saturation binding experiments in the presence of M2 
allosteric modulators and some radiolabeled dibenzodiazepinone compounds highlighted a 
competitive mechanism suggesting a dualsteric binding mode [47,48].  
N
HN
O
O
N
DIBA (6)
UNSW-MK250 (7)
N
NR
R R=
NR
N
N
O
NH
HN
O
O
NH
HN
O
N
N
UNSW-MK262 (8)
R
R
N
NR
O
N
SN
NUR-SK75 (9)  
Figure 5. Structures of homo-hetero dimeric dibenzodiazepinone M2 derivatives. 
Extending the approach to other GPCRs includes the adenosine A1 receptor with the dualsteric 
ligands LUF6258, VCP746 and VCP171 ((10, 11), Figure 6; VCP171, structure not disclosed). An 
orthosteric adenosine agonist was connected through an alkyl chain linker to a PAM of the PD81,723 
type. The resulting bitopic ligands were evaluated pharmacologically in radioligand displacement 
studies suggesting a dualsteric receptor interaction of LUF6258 [49]. VCP746 was subsequently 
Figure 5. Structures of homo-hetero dimeric dibenzodiazepi one M2 derivatives.
Extending the approach to other GPCRs includes the adenosine A1 receptor wi h the
dual teric ligands LUF6258, 746 and VCP171 ((10, 11), Figure 6; VCP171, structure ot
disclosed). An orthosteric adenosine agonist was conne ted through n alkyl c ain linker to
Molecules 2018, 23, 3230 7 of 28
a PAM of the PD81,723 type. The resulting bitopic ligands were evaluated pharmacologically
in radioligand displacement studies suggesting a dualsteric receptor interaction of LUF6258 [49].
VCP746 was subsequently developed by Valant et al. [50] by inclusion of the PAM (2-amino-4-(2-
(trifluoromethyl)phenyl)thiophen-3-yl)(phenyl)-methanone) in the dualsteric structure. The bitopic
ligand 11 was found to induce significant biased cellular signaling in favor of cytoprotection and to
the detriment of bradycardia side effects.
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The compound THR-160209 ((12), Figure 7) was obtained by Steinfeld et al. [51] by connection of
an orthosteric 3-benzylhydrylpyrrolinyl building block to an allosteric 4-aminobenzylpiperidine motif
using a heptane chain. A significant increase in affinity was noted for the bitopic ligand (12), exhibiting
a certain preference for the M2 AChR compared with its orthosteric or allosteric fragments [25,31].
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The opamine D2-like receptor is object of research as drug target for neuropsychiatric disorders.
The bitopic mode of action with D2 and D3 receptors was demonstrated for the dopaminergic ligand
SB269652 ((13), Figure 8). Only a few years after its publication by Stemp et al. [52,53], SB269652
was described as an atypical bitopic ligand. It behaves like a competitive antagonist with receptor
monomers and allosterically across receptor dimers by changing the ability of ligands to bind the
orthosteric binding pocket on the other protomer of the dimer [54,55].
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A new and potent bitopic sphingosine-1-phosphate subtype 3 receptor (S1P3) antagonist, SPM-354
((15), Figure 8), with in vivo activity was a useful tool to define the spatial and functional properties of
S1P3 in regulating cardiac conduction. SPM-354 can compete with both the allosteric S1P3 selective
agonist CYM-5541 as well as the orthosteric agonist S1P, showing bitopic properties. SPM-354,
a 2-propyl derivative of the previously described SPM242, was chosen for in vivo studies ((14) Figure 8)
because of its improved potency and in vivo efficacy [56,57].Molecul s 2018, 23, x FOR PEER REVIEW  8 of 29 
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All these examples illustrate that this principle is applicable across the GPCR landscape.
Additionally, thanks to the progress in understanding dualsteric ligands, several ligands which
were thought to be allosteric modulators were re-classified later as dualsteric ligands (e.g., 77-LH-28-1
and AC-42 at M1 receptor described below see par. 4.1.4). Hence, one can be optimistic that in the
future, more dualsteric ligands at different GPCRs will be discovered and designed using rational
structure-based drug discovery.
3.2.3. Hybrid Strategies Design
Both orthosteric and allosteric fragments and the linker play an important role in the interaction
with the target protein, thus an optimization process considering these moieties s indisp nsable.
Both p armacophores have to be enhanced separately in a k nd of fragm nt-based design approach,
investigating the chemic l environment of the two bindi g pockets. How ver, one should remember
that the binding of one pharmac phore is influencing the binding of the other moiety. For xa pl ,
i is possible that upon binding of the ligand the receptor goes through conformational changes
cau ing negative coo erativity for the complementa y moiety. Therefore, it is difficult t predict the
pharmacolo ical outcome of such bitopic molecules. Furthermore, t link r must fit perfectly, allowing
the allosteric and rthosteric ragments to reach their target pockets. Length, flexibili y, connection
positio , and chemical characteristics of the linker play a fundamental role in the bitopic interact on.
Bitopic ligands r ge fro the first ombination of agonist-NAM (e.g., iperox -6-pht ) [58] to
agonist-PAM (e.g., iperoxo-BQCAd) [49,50,59,60] and antagonist-NAM (e.g., atr-6-naph) [61] for the M2
and M1 muscarinic receptors. All possible co binations e sily widen the spectrum of opportunities.
Al ernativ approaches may also include the use of bitopic ligands to study the low-affinity
and transient binding sites which are defined as metastable sites [62]. Several r search groups have
hypothesized the existence of such a binding site at the entrance of the receptor to which ligands bind
transien ly [63–68]. If an en rgetical y favorable conformation change of he complex ligand-receptor
occurs, the liga d continues its path down to the orthosteric site wher as oth rwise, its route is
prevent d through dissociation. This metastabl site acts as a selec ivity filter: access is denied
to molecules hat do not have the r quired physico-chemical characteristics for the bindin site.
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Metastable binding sites offer new receptor sections that can be explored, opening new strategic
opportunities in the field of bitopic ligands.
Since several GPCRs are organized in dimeric or oligomeric complexes, respectively, bivalent
ligands intended to target an allosteric and orthosteric binding sites or even two orthosteric sites of
two different protomers in a receptor dimer. This will constitute a new design prospective. Rather than
promoting a ligand-induced dimerization, the bivalent ligands tend to stabilize the pre-existing dimers.
Unique pharmacological properties including receptor selectivity could be achieved as bivalent ligands
are able to bridge different receptor units. Heterodimers can be highly selective compounds targeting
only those tissues in which both receptors are co-expressed. Apart from the opioid receptor field, the
potential of these ligands has been poorly explored up to now [69].
The bitopic approach used for the first time in 2006 by De Amici et al. [70] on the M2 muscarinic
receptor was recently extended in the research field of AD on M1 receptor.
4. Muscarinic Receptor
The muscarinic receptors are involved in diverse functions throughout the body with particular
focus on the bladder, gastrointestinal tract, eye, heart, brain, and salivary glands [71]. Physiologically,
these functions are activated and deactivated selectively thanks to the specific tissue distribution of
receptors and the existence of five different receptor subtypes (M1–M5). The M1-type muscarinic
AChRs, predominantly expressed in the hippocampus and cerebral cortex, play a central role in
cognitive processing, memory, and learning. Since structure and density of these AChRs remain almost
unchanged in the disease state, the M1 receptor is considered a very promising target to increase the
cholinergic tone [72].
Highly subtype selective drugs are needed in order to avoid side effects originating from
unwanted receptor activation or inhibition [38]. A number of M1 muscarinic agonists was developed
to treat AD. These are promising agents as they display significant neurotrophic effect, decrease
β-amyloid plaque deposition, and improve oxidative stress-induced damage. Several compounds
have shown an efficacy on the M1 as a therapeutic target for the AD as they not only enhance the
cholinergic functions but can also shift the APP (amyloid precursor protein) processing towards
the nonamyloidogenic pathway through activation of protein kinase C, the metalloproteinase
domain 17 (ADAM17), and a disintegrin [3]. Activation of M1 muscarinic receptors attenuates
tau hyperphosphorylation via glycogen synthase kinase-3b (GSK-3b) inhibition, reduces β amyloid
peptide levels, and increases ERK activation and potentiation of NMDA receptors [38,73,74].
Considerable efforts were made to obtain agonists for M1 but their off-target effects preclude
the therapeutic use. Various agonists for M1 muscarinic receptor including arecoline ((16), Figure 9)
CI-1017 ((17), Figure 9), xanomeline ((18), Figure 9), tazomeline ((19), Figure 9), talsaclidine ((20),
Figure 9) and milameline ((21), Figure 9) do not show sufficient selectivity for the M1 subtype. The
most prominent candidates in the past few years were the M1 muscarinic agonists AF102B ((22),
Figure 9) (cevimeline; approved in the USA and Japan for Sjogren’s Syndrome and having excellent
pharmacokinetic properties), AF150(S) ((23), Figure 9) and AF267B ((24), Figure 9) which additionally
show a significant neurotrophic effect, inhibit Aβ and oxidative stress induced cell death as well as
apoptosis in PC12 cells transfected with the M1 muscarinic receptor [5,75].
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identified by high throughput screening (HTS) and virtual screening at GlaxoSmithKline, unraveling 
a molecule with improved binding and pharmacokinetic parameters. For 30, good M1 agonist 
potency, intrinsic activity, and subtype selectivity for M1 are reported [77,78]. 
F rther ore, the M1 selective agonist lead can idates VU0364572 ((25), Figure 10) and VU0357017
((26), Figure 10) were tested on cell lines as well as animal models and exhibited encouraging as well
as effective properties on various arameters. The c mpound VU0357017 not only showed excellent
M1 subtype selectivity but also a good blood brain barrier (BBB) penetration and in vivo efficacy [38].
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Some highly M1-selective allosteric agonists must also be mentioned here which do not require
an orthoster bound to the receptor for activation. For example, the TBPB allosteric agonist ((28),
Figure 11) interacts with slightly different binding domains of the M1 receptor which are all adjacent
to the orthosteric site. LuAE51090 ((29), Figure 11) displayed a high degree of selectivity when tested
in a broad panel of GPCRs, ion channels, transporters, and enzymes, and showed an acceptable
pharmacokinetic profile and BBB penetration properties in vivo [76]. Compound 30 (Figure 11) was
identified by high throughput screening (HTS) and virtual screening at GlaxoSmithKline, unraveling a
molecule with improved binding and pharmacokinetic parameters. For 30, good M1 agonist potency,
intrinsic activity, and subtype selectivity for M1 are reported [77,78].
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Figure 11. Structures of 1 allosteric agonists.
Both the comparison of the allosteric agonists among each other and even with M1-PAMs reveals
structural similarities. They all consist of an heterobicycle system with at least one nitrogen atom and
a carbonyl group close to the nitrogen. Furthermore, the heterocycle is connected to piperidine rings
which are linked to another cyclic moiety.
4.1. Design of Hybrid Compounds to Investigate the Muscarinic Receptor
The allosterically less conserved site of the mAChR which is located in the extracellular vestibule
(ECV) and separated from the orthosteric pocket by a tyrosine lid [79] lends itself well as binding site
for new dualsteric ligands. The close proximity of the orthosteric and the allosteric subdomains, a
typical feature of the Class A GPCRs, allows the dualsteric compounds to simultaneously interact with
the two bind ng sites.
The chemical space between the orthosteric and allosteric portions of the M2 receptor was
investigated thanks to the pharmacological analysis of Iper-8-naph ((5b-C8), Figure 4) [80,81],
McN-A-343 ((31), Figure 12), and its fragments and analogues [82].
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The long-known partial agonist McN-A-343 interacts with the allosteric EL2 vestibule
through its 3-chlorphenylcarbamate. The binding to the orthosteric sites is guaranteed by the
tetra ethyla oniu cation. The t o parts are linked via a rigid butynyl chain. o ever, this
olecule is probably too small to entirely occupy the allosteric pocket and thereby achi ves no subtype
selectivity. It binds to both M2 and 4 receptors [31].
Iper-8-naph is a partial agonist at the 2 receptor. The partial agonis of ost of the dualsteric
agonists depends on both the dualsteric binding ode itself and on the dyna ic equilibriu of
ultiple inactive and active states, i.e., the ligand binding ense ble. In the “dualsteric binding
ode”, iperoxo is boun to the orthosteric pocket while the allosteric naphthalimide moiety protrudes
towards the extracellular part of the receptor. This pos is re ponsible for a functionally selective
activation of the G proteins and cellular signaling [81,83]. In the alternative pose, which is a “purely
allosteric binding mo e”, the entire bitopic ligand (both the orthosteric and the allosteric moieties)
is in the allosteric vestibule. In this case, the inactive receptor conformation is stabilized. It would
be difficult to pharmacologically distinguish the “flip-flop” mechanism from a ligand with a purely
bitopic binding mode. In case of the iperoxo-dualsteric derivatives at the M2R, the bitopic mode of
interaction was validated by the following experiments: radioligand binding analysis, in wild-type and
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mutant receptors, and downstream signaling assays in addition to receptor docking simulations [34].
Partial agonism is the direct consequence of this dynamic balance. Measuring the partial agonism
depends on the affinity of the two pharmacophores and of the dualsteric ligand itself for the respective
binding sites [30].
4.1.1. BQCAd Hybrid Derivatives
The same approach was applied for exploring the M1 receptor binding pockets. Among several
selective M1 allosteric modulators known, the promising group of N-benzyl quinolone carboxylic acids
(BQCAs) was selected as positive allosteric moieties of these dualsteric M1 hybrids [59,60]. The BQCA
allosteric modulator ((32a), Figure 13) was first described by the Merck laboratory. The compound
is a positive allosteric modulator, an allosteric agonist, and exhibits pure subtype selectivity for the
M1 receptor: no agonism, antagonism, nor potentiation activity was observed at other mAChRs up to
100 µM. The concentration of ACh which needed to activate the receptor decreased up to 129-fold in
the presence of BQCA and an inflection point of 845 nM is reported in the presence of 3 nM ACh. Its
allosteric modulation is mediated by the interaction with the residues Y179 and W400, suggesting the
binding of BQCA to the "common" allosteric site [84,85]. As an orthosteric fragment, the non-selective
superagonist iperoxo ((33), Figure 13) [59] and the endogenous ligand ACh were linked to the BQCA
derivative (BQCAd ((32b), Figure 13)) [60]. The two parts were connected by alkylene chains of
different lengths (C4, C6, C8, C10) ((34a, b, c, d), Figure 13).Molecules 2018, 23, x FOR PEER REVIEW  13 of 29 
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The compounds showed
1. subtype selectivity: receptor activation and signaling pathway studies performed with (dynamic
mass redistribution) DMR in the presence and absence of specific Gi and Gq signaling blockers
indicate a preferentially Gq mediated signal of the hybrids.
2. partial agonism which may provide controlled activation without overdriving the M1 signaling
and with possible i proved side effect profile over the control of cognition [86].
3. pote cy and efficacy dependency on the l ngth of the chain and the substitution pattern
of the allosteric fragment. Elongating the chain from C4 to C6 switches the receptor fractional
occupancy from the inactive, purely allosteric pose to the active binding pose which defines the
efficacy of the dualsteric ligands [87].
The interaction of these compounds with the M1 muscarinic receptor was further investigated
by Fluorescence Resonance Energy Transfer (FRET) measurements in a living cell system for a closer
understanding of the receptor movement. Here, some other ligands were added to the hybrid
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series including longer chained (C8, C10) compounds and ACh hybrids ((35a,b,c,d), Figure 13) [60].
The optimal linker length for the activation of the receptor was confirmed to be a C6 chain,
e.g., in the case of iperoxo-C6-BQCA with a maximal detected signal of about 24% compared to
100 µM of the iperoxo reference. Surprisingly, a new receptor conformation was observed: a FRET
signal with opposite direction to the typical agonist signal occurred for the longer chain hybrids.
How this unknown receptor activation process at a molecular level is connected with the bitopic
compound interaction mode, the different G-protein activation, β-arrestin recruitment, or further
downstream signaling must be investigated to completely understand this unexpected M1 receptor
arrangement. The distinct receptor movement that occurs upon binding of dualster ligands may help to
illuminate the interplay between G proteins and β-arrestins preferentially coupling to different receptor
conformations [88]. Particularly within the M1 pharmacology, functionally selective properties can
be exploited to characterize which signaling outcomes would address neuropsychiatric illnesses [89].
Of note, replacing the flexible alkyl chain with a rigid alkynylbenzene linker ((36), Figure 14) leads to
a delayed FRET signal, indicating slower receptor kinetics. The compound with a flexible chain of
corresponding length afforded a sharper FRET signal, indicating the responsibility of the rigidification
in the kinetic modification [60,90].Molecules 2018, 23, x FOR PEER REVIEW  14 of 29 
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A further step in the study of M1 activation processes was performed with the synthesis and
pharmacological investigation of the first new photo-switchable dualsteric ligand. Agnetta et al. [90]
designed a pharmacological tool in which the photochromic azobenzene moiety was inserted as a
spacer in the hybrid compound. Regarding the time course of M1 activation, compound 37 was found
to be as slow as with the rigid compound, underlining the fundamental role of the chain structure
of the dualsteric hybrids in the M1 receptor kinetic. More interestingly, with the BQCAAI ((37),
Figure 14) compound, the drastic influence of the iperoxo-BQCA hybrid geometry on the activity of
the compound was demonstrated. A simple light-induced isomerization from the cis to the less stable
trans BQCAAI isomer turns the antagonist compound into an agonist.
4.1.2. LY593093
Another allo/ortho partial agonist hybrid was designed at Eli Lilly: LY593093 ((38), Figure 16).
The molecule displaced the [3H] NMS antagonist from M1 muscarinic receptor (pKi of 6.21) without any
effect on [3H] NMS binding at the M3-M5AChR and stimulating β-arrestin recruitment. Additionally,
LY593093 had no modulatory role in potentiating ACh functional activity and the binding was not
affected by an increasing concentration of the PAM BQCA, indicating that the interaction between
LY593093 and M1AChR is different from the interaction of the receptor with the endogenous ligand
ACh. High subtype selectivity is achieved through multiple points of binding pocket interactions
which was shown in the docking model [86]. Binding was also observed for the M2 receptor, but
in terms of functional activity the Eli Lilly compound is 5 and 120 times more potent on M1 AChR
than on other muscarinic receptor subtypes and shows an Emax at least 2-fold higher [91]. Progression
through clinical trials was however interrupted due to its modest brain penetration.
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4.1.3. AC-42 and AC-260584
The allosteric and orthosteric mode of action was also demonstrated by means of a combination of
functional and binding assays for the AC-42 compound ((39), Figure 17). The compound slows down
the dissociation of [3H]NMS from the M1 muscarinic receptor, indicating its allosteric capabilities;
moreover, in equilibrium binding studies, AC-42 almost completely inhibits the binding of the
[3H]NMS orthosteric probe and, in the functional test IP1, the antagonist atropine decreases the
potency of the ligand in a concentration-dependent manner. Later findings indicated an additional
orthosteric binding pose of the ligand [2,92,93]. AC-42, unlike oxo-M, arecoline, and pilocarpine,
is unable to promote M1-Gαi1/2 protein coupling, proving the ability of bitopic ligands to activate
different down streaming effectors [94]. AC-260584 ((40), Figure 17), the orally bioavailable and
structurally related compound with greater potency and efficacy than AC-42, was initially defined as
an allosteric agonist. Mutation of amino acids in the TM3 of the M1 receptor (ACh binding site) affects
the binding of the compound and hence supports the hypothesis of the bitopic behavior [95].
4.1.4. 77-LH-28-1
7 -LH-28-1 ((41), Figure 17), a close structural analogue of AC-42, was initially described
as an allosteric agonist. However, it might have a bitopic binding mode because the antagonist
scopolamine is able to shift its dose-response curve rightward indicating an orthosteric binding mode.
Further evidence supporting this theory is the competition at the NMS-occupied receptor with a
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prototypical muscarinic negative allosteric bis-quaternary phthalimidopropyl modulator (heptane-
1,7-bis(dimethyl-3′-phthalimidopropylammonium bromide, abbreviated as C7/3-phth) [92].
77-LH-28-1 was, however, used as an allosteric fragment of the bitopic hybrids synthesized
by Piergentili et al. [89] The compounds containing xanomeline as orthosteric fragment were
pharmacologically investigated as described below (See par. 5.1.4).Molecules 2018, 23, x FOR PEER REVIEW  16 of 29 
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5. Acetylcholinesterase (AChE)
The decreasing cholinergic tone is one of the physiological reasons of the debilitating AD. To switch
off a cholinergic signal, ACh is catabolized by the acetylcholinesterase (AChE) which hydrolyzes the
ester of the neurotransmitter to acetic acid and choline. The enzyme also appears to be involved in the
aggregation of Aβ by a peripheral anionic site (PAS) in addition to its classical enzymatic hydrolysis
of ACh [96,97]. AChE inhibitors compensate the cholinergic tone in the synaptic transmission and
thus, because of an augmenting ACh concentration, usually relieve the symptoms and can decrease
the rate of cognitive decline for some months. However, they are not able to arrest disease progression
and inexorable neurodegeneration [27]. Already in 1991, Sussman et al. described the enzyme as a
narrow cavity that drives the substrate through a peripheral anionic site (PAS) to the catalytic site
(CAS), where the catalytic triad Glu-His-Ser is located [98]. (Figure 18).
Figure 18. 3 structure of native torpedo californica ChE. The catalytic triad in red, Trp84 in the C S,
Trp279 at the P S, and the bottleneck residue Phe330 in blue. Reproduced ith per ission fro [99].
o ledge of the active site and of the exact function f each amino acid of the catalytic triad
allowed the discovery of enz matic inhibi ors. The AChE inhibitors (AChEIs) donepezil, gala tamine,
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rivastigmine ((1–3), Figure 1), and tacrine ((42), Figure 19) were successfully developed and approved
by international authorities. Later, tacrine was withdrawn from the market due to a significant
hepatic toxicity.Molecules 2018, 23, x FOR PEER REVIEW  17 of 29 
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Rivastigmine is a pseudo-irreversible arylcarbamate inhibitor of both AChE and BChE. Clinical 
studies comparing the effect of the two approved drugs donepezil (only AChE inhibition) and 
rivastigmine (AChE and BChE inhibition) revealed an additional benefit in daily living, global 
function, and behavior for rivastigmine in patients with wild-type BuChE allele due to the dual 
inhibition of AChE and BChE [101–103]. Anyway, the use of AChEIs for AD is considered a 
suboptimal therapy and is still under discussion [104]. This review will not give details about all 
AChEIs because they were already summarized excellently in ref. 105–108 [105–108].  
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5.1.1. Tacrine Hybrids 
In order to investigate the potency of tacrine for the inhibition of AChE with simultaneously 
reduced hepatotoxicity, tacrine was intensively used for the development of hybrid molecules. Pang 
et al. found a bis-C7-tacrine homodimer ((43-C7), Figure 21) exhibiting a 1000-fold higher AChE 
inhibitory potency in rats than the monomer, indicating the absence of steric interaction problems in 
the narrow cavity preceding the catalytic site of the enzyme. The tacrine dimers are able to establish 
interactions with both the catalytic and the peripheral site. A shorter tether (<5 methylene units) 
hampers the simultaneous binding to both interaction sites of AChE (dual-site binding). In addition, 
the lipophilicity of the hybrid was found to be increased compared to tacrine itself [109,110]. 
Figure 19. Structure of tacrine.
These compounds inhibit the enzyme differently: several ligands, e.g., galantamine, covalently
bind to the serine residue and form a bond that is stable for about 15–20 min; during this time, the
enzyme is inhibited. Tacrine blocks the passage of the neurotransmitter due to a strong pi-stacking
interaction with Trp84 (Figure 20) [100].
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Figure 20. Overlay of the trigonal crystal structure of tacrine (black) and Tc AChE (gray) complex:
showing the catalytic anionic site, aromatic gorge, and peripheral anionic site. Reproduced with
permission from [100].
Rivastigmine is a pseudo-irreversible arylcarbamate inhibitor of both AChE and BChE. Clinical
studies comparing the effect of the two approved drugs donepezil (only AChE inhibition) and
rivastigmine (AChE and BChE inhibition) revealed an additional benefit in daily living, global function,
and behavior for rivastigmine in patients with wild-type BuChE allele due to the dual inhibition of
AChE and BChE [101–103]. Anyway, the use of AChEIs for AD is considered a suboptimal therapy
and is still under discussion [104]. This review will not give details about all AChEIs because they
were already summarized excellently in ref. [105–108].
5.1. Design of Hybrid Compounds Inhibiting the Cholinesterase
5.1.1. Tacrine Hybrids
In order to inves igate the potency of tacrine for th inhibition of AChE with simultaneously
reduced hepatotoxicity, acrine was intensively used for development of hyb id molecules. Pang
et al. found a bis-C7-tacrine omodimer ((43-C7), Figure 21) xhib ting a 1000-fold high r AChE
i hibitory potency in ra s than the mo omer, indicating the absence of st ric interaction problems in
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the narrow cavity preceding the catalytic site of the enzyme. The tacrine dimers are able to establish
interactions with both the catalytic and the peripheral site. A shorter tether (<5 methylene units)
hampers the simultaneous binding to both interaction sites of AChE (dual-site binding). In addition,
the lipophilicity of the hybrid was found to be increased compared to tacrine itself [109,110].Molecules 2018, 23, x FOR PEER REVIEW  18 of 29 
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Table 1. Cholinesterase activity and cytotoxicity of the M2 bitopic compounds and tacrine hybrids. 
BChE from equine serum, AChE from electric eel. [110]. 
Compound 
BChE 
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AChE 
pIC50 [M] 
Cytotoxicity 
HEP G2 IC50 [μM] 
Tacrine (42) 8.57 7.60 111 (±2.28) 
Phth-7-iper (5a-C7) 5.19 4.83 n.d. 1 
Phth-8-iper (5a-C8) 5.13 4.89 n.d. 1 
Phth-9-iper (5a-C9) 4.88 4.80 n.d. 1 
Phth-10-iper (5a-C10) 5.37 5.26 n.d. 1 
Naph-7-iper (5b-C7) 6.69 6.04 n.d. 1 
Naph-8-iper (5b-C8) 6.46 6.10 n.d. 1 
Naph-9-iper (5b-C9) 6.49 6.44 n.d. 1 
Naph-10-iper (5b-C10) 6.99 6.50 n.d. 1 
Tac-7-Tac (43-C7) 9.14 10.48 <1.38 (±0.08) 
Tac-10-Tac (43-C10) 9.34 9.00 <1.25 (±0.00) 
5.1.2. Tacrine/Iperoxo hybrids
Some bitopic ligands combining the M2 allosteric structure of the allosteric modulator W84
and naphmethonium and the non-selective superagonist iperoxo, rationally developed as M2
subtype-selective ligands ((5a,b-C7,8,9,10), Figure 4), were tested for the inhibitory activity of the
AChE and found to have modest activity. The potency is influenced by the length of the linker chain
connecting the orthosteric and allosteric sites. The longest chains result in a higher activity: the
decamethylene chain seems to span the AChE binding gorge, allowing the quaternary ammonium
head of iperoxo to be localized in the PAS region. Compounds containing the naphthalimide
portion ((5b-C7,8,9,10), Figure 4) show stronger inhibition than those containing the phthalimide
part ((5a-C7,8,9,10), Figure 4). When replacing the iperoxo moiety with an isoxazole ring, almost no
AChE/BuChE inhibition was observed ((44-C4,6,8), Figure 22; Table 1) [80].
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Table 1. Cholinesterase activity and cytotoxicity of the M2 bitopic compounds and tacrine hybrids.
BChE from equine serum, AChE from electric eel. [110].
Compound BChEpIC50 [M]
AChE
pIC50 [M]
Cytotoxicity
HEP G2 IC50 [µM]
Tacrine (42) 8.57 7.60 111 (±2.28)
Phth-7-iper (5a-C7) 5.19 4.83 n.d. 1
Phth-8-iper (5a-C8) 5.13 4.89 n.d. 1
Phth-9-iper (5a-C9) 4.88 4.80 n.d. 1
Phth-10-iper (5a-C10) 5.37 5.26 n.d. 1
Naph-7-iper (5b-C7) 6.69 6.04 n.d. 1
Naph-8-iper (5b-C8) 6.46 6.10 n.d. 1
Naph-9-iper (5b-C9) 6.49 6.44 n.d. 1
Naph-10-iper (5b-C10) 6.99 6.50 n.d. 1
Tac-7-Tac (43-C7) 9.14 10.48 <1.38 (±0.08)
Tac-10-Tac (43-C10) 9.34 9.00 <1.25 (±0.00)
Phth-4-isoxo (44-C4) 4.07 19.12% inhib. at 100 µM n.d. 1
Phth-6-isoxo (44-C6) 4.41 32.91% inhib. at 100 µM n.d. 1
Phtal-8-isoxo (44-C8) 5.10 4.17 n.d. 1
Tac-7-iper (45-C7) 8.29 8.76 >160 (±0.00)
Tac-10-iper (45-C10) 8.75 9.81 32.2 (±0.41)
1 n.d.: not determined.
Starting from this finding, new hybrids with multitarget potential ((45), Figure 22) were
synthesized consisting of a tacrine and an iperoxo moiety, aiming at higher inhibitory activity for
the AChE and BChE [111]. The idea was to combine the iperoxo affinity for the M1 and M2 receptor
with the AChE inhibitory activity. Tacrine can serve as both an allosteric modulator for M receptor
and as inhibitor of AChE [112–114]. In particular, Tac-10-iper ((45-C10), Figure 22) was an extremely
potent inhibitor with an IC50 value of 9.81 (AChE from electric eel; tacrine IC50 7.60) and 8.75 (BChE
from equine serum; tacrine IC50 8.57) which is even better than tacrine itself. Moreover, it shows
less cytotoxicity.
Docking studies show a similar binding mode of compounds 5a-C10 and 5b-C10 to Tac-10-iper
((45-C10) in the CAS and PAS regions of AChE (Figure 23). The remarkably lower affinity of 45-C10
is probably due to the additional quaternary ammonium group of the Phtal- and Naph-compounds
which causes a much higher desolvation penalty in comparison to the uncharged alkylene chain.
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ability of Tac-7-Iper and Tac-10-Iper ((45-C7, 45-C10, Figure 22) to activate the M1 muscarinic receptor
in a nanomolar range (Volpato et al., unpublished results). Further studies are necessary for developing
uncharged molecules that could cross the BBB; so far, it is promising to see that compounds with a
single positive charge are associated with better activity than compounds with two charges [110,111].
5.1.3. Tacrine/Xanomeline Hybrids
A similar dualsteric strategy was previously employed by the Decker group [114]. They designed
and synthesized tacrine and xanomeline hybrid compounds ((46a), Figure 24). The rational design of
these hybrids was aimed at a triple mechanism of cooperative action: activation of the M1 receptor
through the xanomelinic molecular portion ((18), Figure 9), positive allosteric modulation regarding
orthosteric agonists at the M1 receptor subtype thanks to the allosteric properties of tacrine, and
increasing the amount of ACh in cholinergic synapses due to the AChE inhibiting activity [114].
Xanomeline is an M1 agonist but unfortunately also shows some affinity to the M4 receptor. Therefore,
parasympathetic side effects including bradycardia, increased gut motility, and salivation occur.
Binding studies on cloned human muscarinic receptors did not detect the selective binding capacity
between M1 and M4. Xanomeline is well-known for its anti-dementia properties in vivo, and the
attenuation of cognitive decline in 6 months clinical trial human patients proved its activity against
AD [115]. The metabolic instability due to an extensive first-pass metabolism, the well-known
cholinomimetic side effects, and its undesirable activity for the dopaminergic and 5-TH receptors
(serotonin receptors) rendered the compound an insufficient clinical candidate [116,117]. Xanomeline
induces a specific mode of M1 receptor activation by interacting with a site that does not fully
overlap with the endogenous, orthosteric binding site. Differences in binding kinetics [118] and a
wash-persistent binding, probably arising from a hydrophobic interaction of xanomeline’s O-hexyl
chain with the membrane lipids surrounding the receptor [119,120], may explain its functional
selectivity [121].
The xanomeline portion was connected to the tacrine with amide bridges of different length
(10-17 atoms spacer). A clear increase of AChE inhibition was observed by increasing the spacer chain
from pIC50 of 7.20 to 8.21. The hybrids inhibited the AChE with similar or higher potency compared
to tacrine but did not activate the M1 receptor. Instead of a simultaneous allosteric/orthosteric
binding, the ligands seem to prefer a purely allosteric binding even in the orthosterically free receptor.
These findings were supported by in vivo studies in rats with a representative compound ((46a),
Figure 24). The cognitive deficits induced by administration of scopolamine were enhanced by the
purely M1 allosteric interaction of the hybrid 46a counterbalancing its high ChE-inhibitor properties.
The desired triple mechanism of action unfortunately did not take place with these compounds. This
demonstrates the difficulty of predicting the intrinsic activities of the chosen component molecules
and the importance of their cooperativity, which must lead to a balanced compromise.
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of orthosteric or allosteric pharmacology depending on the experimental assay conditions [122], was 
incorporated into a series of allo/ortho hybrid ligands, hypothesizing a shared function of the 
common chain ligand structures of xanomeline and 77-LH-28-1 ((48a,b), Figure 25). With a merging 
approach, the two scaffolds were fused into the new hybrids, aiming for a better understanding of 
the allosteric pocket and of the bitopic binding pose of 77-LH-28-1 itself. 
  
i r . i i it ist .
5.1.4. 77-LH-28-1/Xanomeline Hybrids
As already mentioned above, compound 77-LH-28-1 ((47), Figure 25) displaying mixed modes
of orthosteric or allosteric pharmacology depending on the experimental assay conditions [122],
was incorporated into a series of allo/ortho hybrid ligands, hypothesizing a shared function of the
common chain ligand structures of xanomeline and 77-LH-28-1 ((48a,b), Figure 25). With a merging
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approach, the two scaffolds were fused into the new hybrids, aiming for a better understanding of the
allosteric pocket and of the bitopic binding pose of 77-LH-28-1 itself.Molecules 2018, 23, x FOR PEER REVIEW  21 of 29 
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The phar acological investigation of these hybrid derivatives evidenced an affinity at the 1
receptor higher than 77-L -28-1 and lo er than xano eline. In general, hybrid co pounds sho ed
either a eak agonistic or an antagonistic activity profile (M1 and M4) in all the functional assays and
the activity/selectivity was related to the length of the spacer. The highest affinity values are associated
with a seven- or nine-atom length carbon chain, indicating that the two pharmacophores probably
interact with two distinct sites located at a distance of 7 to 9 methylene oieties. Xano-9-77-LH-28-1
exhibited higher efficacy for the β-arrestin2 engagement in M1. In line with the reported functional
properties of the aliphatic chain moiety in 77-LH-28-1, these results indicate that the linker extension
affects the orthosteric binding site [89].
6. Nicotinic Receptor
Nicotinic receptors are transmembrane pentameric proteins that belong to the superfamily of
ligand-gated ion channels, composed of α and β subunits assembled around a central hydrophilic pore
that mediates the flow of the cations K+, Na+, and Ca2+. Different combinations of subunits generate a
variety of nAChR subtypes with distinct electrophysiological properties and brain localization [123,124].
nAChRs are considered to play an important role in neuroprotection due to a concentration dependent
interaction with the β-amyloid peptide. In particular, the physiological concentration of Aβ may
directly stimulate the α7 nicotinic receptors while an increasing pathological concentration of Aβ
damages the cholinergic responses mediated by α7 and α4β2 receptors.
6.1. Design of Hybrid Compounds to Investigate the Nicotinic Receptor
1-(2-Methoxybenzyl)-Piperazine-Carbazole Hybrids
The mutual interaction between Aβ and cholinergic transmission was investigated. Following
a ligand-based approach, hybrid compounds addressing both systems were synthetized and
subsequently pharmacologically studied. The molecules combine an α7 agonist and a carbazole moiety
having AChE inhibition properties ((49a,b), Figure 26) [125]. Substituted carbazoles are able to interact
with the narrow inner part of the AChE enzyme gorge and also present anti-amyloidogenic activity.
This moiety was connected with the α7 agonistic activity of 1-(2-methoxybenzyl)-piperazine [126].
It was selected because of the structural similarity with the ethyl-(2-methoxybenzyl)-amine group
recognizing the AChE catalytic site [127,128].
The resulting multitarget compounds, in particular compound ((49b), Figure 26), presented AChE
inhibition activity in a micromolar concentration range (compound with six methylene unit spacer
IC50 = 0.773 µM). AChE inhibition was strongly dependent on the linker elongation. In particular,
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compounds with a shorter chain in the series had lower IC50 values. In radioligand binding assays,
the compounds exhibited a micromolar affinity profile with Ki values ranging from 15 to 120 µM in
the displacement of [3H]-epibatidine and [125I]-α-bungarotoxin from α4β2 and α7 receptor subtypes in
rat cortex, without discrimination in the receptor subtype. The action towards nAChRs was tested
by using two-electro voltage clamps. Unfortunately, the compounds only reached 15–22% of the
response (reference 100 µM Ach) at α4β2 receptors. No response was observed at the α7 receptor,
possibly due to its lower sensibility to ACh or its faster desensitization. Interestingly, their inhibition
ability at 10 µM of Aβ fibril formation, proved with a ThT-based fluorimetric assay, is similar to the
anti-aggregating and blocking fibril formation activity of curcumin [129] (28-36% compared to 34.4%
of curcumin). Synergistically, a weak perturbation of one of the systems involved in the cholinergic
neurotransmission (AChE, nAChRs) and amyloid aggregation could be sufficient to modify the entire
scenario. Therefore, the compounds are a suitable starting point for further optimization.
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7. Looking to the Future for AD Hybrids Tools 
The hybrid compounds targeting different biological proteins and dualsteric ligands addressing 
distinct parts of the same target or a combination of both strategies provide pharmacological tools 
that could expand horizons in medicinal chemistry. All the hybrid examples reported provide 
additional useful and important information regarding their target, showing that the development 
of bivalent compounds is not only possible but also promising in offering new pharmacological 
instrumentation. Poor drugability is the direct consequence of the relatively high molecular weight 
of bitopic ligands which prevents their progression in drug development. The bivalent compounds 
can provide new useful information regarding protein-ligand interactions anyway, understanding 
the intricate relationship between receptor activation, conformational dynamics, signaling profile in 
the cholinergic system, and the connection between different hallmarks of AD. Advantages such as 
better selectivity, signaling bias, or reduced toxicity of some hybrids can be further exploited through 
a subsequent fragment based process trying to reduce physicochemical issues but keeping the 
precious improvement obtained. The simultaneous attack on several fronts seems to provide insights 
that may be the key to opening new glimpses in the cholinergic field of the AD. 
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7. Looking to the Future for AD Hybrids Tools
The hybrid compounds targeting different biological proteins and dualsteric ligands addressing
distinct parts of the same target or a combination of both strategies provide pharmacological tools
that could expand horizons in medicinal chemistry. All the hybrid examples reported provide
additional useful and important information regarding their target, showing that the development
of bivalent compounds is not only possible but also promising in offering new pharmacological
instrumentation. Poor drugability is the direct consequence of the relatively high molecular weight
of bitopic ligands which prevents their progression in drug development. The bivalent compounds
can provide new useful information regarding protein-ligand interactions anyway, understanding
the intricate relationship between receptor activation, conformational dynamics, signaling profile in
the cholinergic system, and the connection between different hallmarks of AD. Advantages such as
better selectivity, signaling bias, or reduced toxicity of some hybrids can be further exploited through a
subsequent fragment based process trying to reduce physicochemical issues but keeping the precious
improvement obtained. The simultaneous attack on several fronts seems to provide insights that may
be the key to opening new glimpses in the cholinergic field of the AD.
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